Photodynamic therapy for focal ablation of the prostate

World J Urol. 2010 Oct;28(5):571-6. doi: 10.1007/s00345-010-0554-2. Epub 2010 May 9.

Abstract

Although in early stages of clinical development, photodynamic therapy (PDT) shows promise in delivering focal treatment of both primary and post-radiotherapy prostate cancer. This article will review the mechanism of action of PDT, previous research using PDT for treating prostate cancer including the development of newer vascular-acting photosensitizers, and the potential advantages and disadvantages of PDT in delivering focal therapy.

Publication types

  • Review

MeSH terms

  • Dihematoporphyrin Ether / therapeutic use
  • Humans
  • Male
  • Mesoporphyrins / therapeutic use
  • Metalloporphyrins / therapeutic use
  • Photochemotherapy* / adverse effects
  • Photosensitizing Agents / therapeutic use*
  • Prostatic Neoplasms / drug therapy*
  • Treatment Outcome

Substances

  • Mesoporphyrins
  • Metalloporphyrins
  • Photosensitizing Agents
  • motexafin lutetium
  • Dihematoporphyrin Ether
  • temoporfin